文献速递糖尿病

2型1型糖尿病阶段β细胞功能与胰岛素清除轨迹:自然史及对teplizumab的反应

Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab.
PubMed 文献 · Diabetologia · 2024-11-19

本研究利用口服最小模型(OMM)指标分析TN10试验数据,描述安慰剂治疗者2期1型糖尿病自然史及teplizumab早期代谢反应。结果显示安慰剂组胰岛素分泌下降而teplizumab组上升;慢进展者胰岛素清除显著下降;基线胰岛素分泌较高(p=0.027)和12个月胰岛素清除降低(p=0.045)预测进展更慢;3个月胰岛素分泌下降>25%对快速进展者特异性0.95。

要点

  • 安慰剂组胰岛素分泌下降,teplizumab组上升,慢进展者维持分泌。
  • 慢进展者胰岛素清除较快速进展者显著下降。
  • 3个月胰岛素分泌下降>25%识别快速进展者特异性0.95。

核心结论

  • OMM指标可刻画2期1型糖尿病的代谢异质性,识别快慢进展者差异及免疫治疗的异质性影响,提示设计解读临床试验时需考虑这些差异。

研究设计与样本

  • 分析TN10试验数据,纳入28例安慰剂组和39例teplizumab组受试者,于基线及随机后3、6、12个月评估OMM指标。
  • 每组内按进展速度分为慢进展者(进展至3期时间>2年)和快进展者(≤2年)。

主要发现

  • 12个月内胰岛素分泌在安慰剂组下降、在teplizumab组上升。
  • 安慰剂慢进展者(n=14)胰岛素分泌和敏感性维持,快进展者(n=14)两者均下降。
  • teplizumab慢进展者(n=28)维持升高的胰岛素分泌,快进展者(n=11)出现轻度代谢下降。
  • 与快进展组相比,两个治疗组中慢进展组的胰岛素清除在基线至3、6、12个月间均显著下降。
  • 基线胰岛素分泌较高(p=0.027)和12个月胰岛素清除降低(p=0.045)预测进展更慢。

关键数值与推荐

  • OMM估算的胰岛素分泌在区分治疗组或预测进展方面优于AUC C肽。
  • 代谢变化与PD-1+ CD8+ T效应记忆细胞相对频率变化平行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: We aimed to analyse TrialNet Anti-CD3 Prevention (TN10) data using oral minimal model (OMM)-derived indices to characterise the natural history of stage 2 type 1 diabetes in placebo-treated individuals, to describe early metabolic responses to teplizumab and to explore the predictive capacity of OMM measures for disease-free survival rate. METHODS: OMM-estimated insulin secretion, sensitivity and clearance and the disposition index were evaluated at baseline and at 3, 6 and 12 months post randomisation in placebo- and teplizumab-treated groups, and, within each group, in slow- and rapid-progressors (time to stage 3 disease >2 or ≤ 2 years). OMM metrics were also compared with the standard AUC C-peptide. Percentage changes in CD8+ T memory cell and programmed death-1 (PD-1) expression were evaluated in each group. RESULTS: Baseline metabolic characteristics were similar between 28 placebo- and 39 teplizumab-treated participants. Over 12 months, insulin secretion declined in placebo-treated and rose in teplizumab-treated participants. Within groups, placebo slow-progressors (n=14) maintained insulin secretion and sensitivity, while both declined in placebo rapid-progressors (n=14). Teplizumab slow-progressors (n=28) maintained elevated insulin secretion, while teplizumab rapid-progressors (n=11) experienced mild metabolic decline. Compared with rapid-progressor groups, insulin clearance significantly decreased between baseline and 3, 6 and 12 months in the slow-progressor groups in both treatment arms. In aggregate, both higher baseline insulin secretion (p=0.027) and reduced 12 month insulin clearance (p=0.045) predicted slower progression. A >25% loss of insulin secretion at 3 months had specificity of 0.95 (95% CI 0.86, 1.00) to identify rapid-progressors and correctly classified the 2 year risk for progression in 92% of participants, with a sensitivity of 0.19 (95% CI 0.08, 0.30). OMM-estimated insulin secretion outperformed AUC C-peptide to differentiate groups by treatment or to predict progression. Metabolic changes were paralleled by relative frequency of change in PD-1+ CD8+ T effector memory cells. CONCLUSIONS/INTERPRETATION: OMM measures characterise the metabolic heterogeneity in stage 2 diabetes, identifying differences between rapid- and slow-progressors, and heterogeneous impacts of immunotherapy, suggesting the need to account for these differences when designing and interpreting clinical trials.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Galderisi A, Sims EK, Evans-Molina C, et al. Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab. Diabetologia. 2024. PMID: 39560746. doi:10.1007/s00125-024-06323-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。